Articles related to BLADDER CANCER

The TROPiCs-04 trial results challenge the current treatment landscape for metastatic urothelial carcinoma, highlighting the need for new strategies post-relapse and the importance of next-generation sequencing in patient selection.

This pivotal study demonstrates that the combination of enfortumab vedotin and pembrolizumab not only extends progression-free survival but also significantly improves overall survival rates in patients with untreated advanced urothelial carcinoma.

This study illuminates the potential of preoperative circulating tumor DNA to redefine the approach to treating high-risk upper tract urothelial carcinoma, offering a nuanced tool for assessing the necessity of neoadjuvant chemotherapy and tailoring patient care.

ESMO Congress 2023 unveils groundbreaking advances in mUC treatments, emphasizing novel therapeutic combinations and the critical role of personalized medicine in improving patient outcomes.

The future of advanced bladder cancer treatment has been crystallized by the findings of the EV302 study, which demonstrated a median overall survival of 31.5 months with enfortumab vedotin-ejfv plus pembrolizumab.

A recent phase 3 trial has shown that the combination of nivolumab and gemcitabine–cisplatin significantly improves survival rates in patients with previously untreated advanced urothelial carcinoma. This combination therapy resulted in a median survival of 21.7 months compared to 18.9 months with gemcitabine–cisplatin alone.